Navigation Links
Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
Date:5/6/2011

SAN DIEGO, May 6, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present at the Bank of America Merrill Lynch 2011 Health Care Conference on Wednesday, May 11, 2011, at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time) at the Encore at the Wynn Las Vegas Hotel in Las Vegas, Nevada. Christen M. Anderson, M.D., Ph.D., Arena's Vice President, Lorcaserin Development, is scheduled to provide a corporate overview.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is intended for weight management. Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, has granted Eisai Inc. exclusive rights to market and distribute lorcaserin in the United States subject to FDA approval of the New Drug Application (NDA) for lorcaserin.

Arena Pharmaceuticals® and Arena® are registered service marks of the company.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the potential therapeutic indication and use, FDA approval and commercialization of lorcaserin; the Eisai collaboration and potential activities thereunder; and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the timing of regulatory review and approval is uncertain; the risk that data and other information related to Arena's research and development programs, including for lorcaserin, may not meet safety or efficacy requirements or otherwise be sufficient for regulatory approval; Arena's response to the FDA's complete response letter to the lorcaserin NDA may not be submitted when anticipated, if at all; the FDA may request other information prior to or after Arena submits such response or approval of the lorcaserin NDA; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; Arena's ability to obtain adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.Contact: Arena Pharmaceuticals, Inc.

Media Contact: Russo PartnersJack Lief

David Schull, PresidentPresident and CEO

david.schull@russopartnersllc.com858.717.2310Cindy McGee

Anthony J. Russo, Ph.D., CEOManager, IR and Corporate Communications

tony.russo@russopartnersllc.com858.453.7200, ext. 1479

212.845.4251
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
2. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
3. Arena Pharmaceuticals Expands GPR119 Patent Portfolio for Type 2 Diabetes
4. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11
5. Arena Pharmaceuticals Announces Upcoming Departure of Chief Financial Officer
6. Arena Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
7. Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application
8. Arena Pharmaceuticals to Host Conference Call and Webcast to Provide Update Following Lorcaserin End-of-Review Meeting With FDA
9. Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD811 for Pulmonary Arterial Hypertension
10. Arena Pharmaceuticals Announces Third Quarter 2010 Financial Results and Reviews Recent Developments
11. Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... April 28, 2016  The blood testing market in ... according to Kalorama Information and The Freedonia Group in ... nucleic acid testing.  The healthcare research firm said that ... developing blood collection stations and in improving testing at ... Information,s report, Blood Testing Market in China ...
(Date:4/28/2016)... , April 28, 2016 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of oral drug ... the upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... in New York . Nadav Kidron ... the conference. Presentation Details:   ...
(Date:4/28/2016)... , April 28, 2016 ... Review, H1 2016" is a report that provides ... helps strengthen R&D pipelines by identifying new targets ... Company Profiles discussed in this H1 ... Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., ...
Breaking Medicine Technology:
(Date:5/3/2016)... , ... May 03, 2016 , ... Ogawa World USA ... its user friendly Samsung tablet and exclusive Smart Application. The Smart 3D combines the ... each massage with a customized user profile and specialized massage program, each user has ...
(Date:5/3/2016)... ... 03, 2016 , ... Octo Consulting Group, Inc. ... services to the federal government, has been awarded a $9.9 million Task Order ... contract in support of the U.S. Army Program Executive Office for Enterprise Information ...
(Date:5/3/2016)... FL (PRWEB) , ... May 03, 2016 , ... Branches, ... both its Grow & Climb children and youth programs in South Miami. Macy’s is ... years. , The Grow Program provides afterschool tutoring, mentoring, enrichment and academic support ...
(Date:5/3/2016)... ... , ... LunchSkins is changing the future of ocean plastic pollution ... away plastic baggies. The mission-driven bags give back to global leaders in the fight ... mission is all about reducing global plastic waste and we’ve teamed up with ...
(Date:5/3/2016)... ... May 03, 2016 , ... The ... issued by the Office of the National Coordinator for Health IT (ONC) with ... action when necessary, including suspending and terminating certifications issued to Complete EHRs and ...
Breaking Medicine News(10 mins):